|
|
Blood, 15 January 2008, Vol. 111, No. 2, pp. 750-760.
Prepublished online as a Blood First Edition Paper on October 17, 2007; DOI 10.1182/blood-2007-03-077222.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival
Robert T. Woodland1,
Casey J. Fox2,
Madelyn R. Schmidt1,
Peter S. Hammerman2,
Joseph T. Opferman3,
Stanley J. Korsmeyer3,
David M. Hilbert4, and
Craig B. Thompson2
1 Department of Molecular Genetics and Microbiology and the Immunology and Virology Program, University of Massachusetts Medical School, Worcester;
2 Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia;
3 Howard Hughes Medical Institute, Harvard Medical School, Dana-Farber Cancer Center, Boston, MA; and
4 Human Genome Sciences, Rockville, MD
We investigated the mechanism by which B lymphocyte stimulator (BLyS)/BAFF, a tumor necrosis factor superfamily ligand, promotes B-cell survival and resistance to atrophy. BLyS stimulation activates 2 independent signaling pathways, Akt/mTOR and Pim 2, associated with cell growth and survival. BLyS blocks the cell volume loss (atrophy) that freshly isolated B cells normally undergo when maintained in vitro while concurrently increasing glycolytic activity and overall metabolism. This atrophy resistance requires Akt/mTOR. We used a genetic approach to resolve the contributions of Akt/mTOR and Pim kinase pathways to BLyS-mediated survival. Pim 2–deficient B cells are readily protected from death by BLyS stimulation, but this protection is completely abrogated by treatment with the mTOR inhibitor rapamycin. Furthermore, rapamycin treatment in vivo significantly reduces both follicular and marginal zone B cells in Pim-deficient but not healthy hosts. BLyS-dependent survival requires the antiapoptotic protein Mcl-1. Mcl-1 protein levels rise and fall in response to BLyS addition and withdrawal, respectively, and conditional deletion of the Mcl-1 gene renders B cells refractory to BLyS-mediated protection. Because BlyS is required for the normal homeostasis of all B cells, these data suggest a therapeutic strategy simultaneously inhibiting mTOR and Pim 2 could target pathogenic B cells.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. L. Hoek, G. Carlesso, E. S. Clark, and W. N. Khan
Absence of Mature Peripheral B Cell Populations in Mice with Concomitant Defects in B Cell Receptor and BAFF-R Signaling
J. Immunol.,
November 1, 2009;
183(9):
5630 - 5643.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. N. Khan
B Cell Receptor and BAFF Receptor Signaling Regulation of B Cell Homeostasis
J. Immunol.,
September 15, 2009;
183(6):
3561 - 3567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gupta, S. R. Dillon, S. C. Ziesmer, A. L. Feldman, T. E. Witzig, S. M. Ansell, J. R. Cerhan, and A. J. Novak
A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation
Blood,
May 21, 2009;
113(21):
5206 - 5216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Meyer-Bahlburg, A. D. Bandaranayake, S. F. Andrews, and D. J. Rawlings
Reduced c-myc Expression Levels Limit Follicular Mature B Cell Cycling in Response to TLR Signals
J. Immunol.,
April 1, 2009;
182(7):
4065 - 4075.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Crowley, J. E. Stadanlick, J. C. Cambier, and M. P. Cancro
Fc{gamma}RIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation
Blood,
February 12, 2009;
113(7):
1464 - 1473.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Tabrizi, H. Niiro, M. Masui, G. Yoshimoto, T. Iino, Y. Kikushige, T. Wakasaki, E. Baba, S. Shimoda, T. Miyamoto, et al.
T Cell Leukemia/Lymphoma 1 and Galectin-1 Regulate Survival/Cell Death Pathways in Human Naive and IgM+ Memory B Cells through Altering Balances in Bcl-2 Family Proteins
J. Immunol.,
February 1, 2009;
182(3):
1490 - 1499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Gandhi, K. Balakrishnan, and L. S. Chen
Mcl-1: the 1 in CLL
Blood,
November 1, 2008;
112(9):
3538 - 3540.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. L. Otipoby, Y. Sasaki, M. Schmidt-Supprian, A. Patke, R. Gareus, M. Pasparakis, A. Tarakhovsky, and K. Rajewsky
BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells
PNAS,
August 26, 2008;
105(34):
12435 - 12438.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|